Enhancement of DNA vaccine potency through linkage of antigen to filamentous bacteriophage coat protein III domain I

TY - JOUR

T1 - Enhancement of DNA vaccine potency through linkage of antigen to filamentous bacteriophage coat protein III domain I

AU - Cuesta, Angel M

AU - Suárez, Eduardo

AU - Larsen, Martin

AU - Jensen, Kim Bak

AU - Sanz, Laura

AU - Compte, Marta

AU - Kristensen, Peter

AU - Alvarez-Vallina, Luis

PY - 2006/4

Y1 - 2006/4

N2 - Although DNA-based cancer vaccines have been successfully tested in mouse models, a major drawback of cancer vaccination still remains, namely that tumour antigens are weak and fail to generate a vigorous immune response in tumour-bearing patients. Genetic technology offers strategies for promoting immune pathways by adding immune-activating genes to the tumour antigen sequence. In this work, we converted a model non-immunogenic antigen into a vaccine by fusing it to domain I of the filamentous bacteriophage coat protein III gene. Vaccination with a DNA construct encoding the domain I fusion generated antigen-specific T helper 1-type cellular immune responses. These results demonstrate that the incorporation of protein III into a DNA vaccine formulation can modulate the gene-mediated immune response and may thus provide a strategy for improving its therapeutic effect.

AB - Although DNA-based cancer vaccines have been successfully tested in mouse models, a major drawback of cancer vaccination still remains, namely that tumour antigens are weak and fail to generate a vigorous immune response in tumour-bearing patients. Genetic technology offers strategies for promoting immune pathways by adding immune-activating genes to the tumour antigen sequence. In this work, we converted a model non-immunogenic antigen into a vaccine by fusing it to domain I of the filamentous bacteriophage coat protein III gene. Vaccination with a DNA construct encoding the domain I fusion generated antigen-specific T helper 1-type cellular immune responses. These results demonstrate that the incorporation of protein III into a DNA vaccine formulation can modulate the gene-mediated immune response and may thus provide a strategy for improving its therapeutic effect.

KW - Adjuvants, Immunologic

KW - Animals

KW - Antigens, Neoplasm/immunology

KW - Cancer Vaccines/immunology

KW - Capsid Proteins

KW - Cytokines/biosynthesis

KW - DNA-Binding Proteins/immunology

KW - Female

KW - Immunity, Cellular

KW - Immunoglobulin G/biosynthesis

KW - Immunoglobulin Variable Region/immunology

KW - Mice

KW - Mice, Inbred BALB C

KW - Recombinant Fusion Proteins/immunology

KW - Th1 Cells/immunology

KW - Vaccination

KW - Vaccines, DNA/immunology

KW - Viral Fusion Proteins/immunology

U2 - 10.1111/j.1365-2567.2006.02325.x

DO - 10.1111/j.1365-2567.2006.02325.x

M3 - Journal article

C2 - 16556264

SN - 0019-2805

VL - 117

SP - 502

EP - 506

JO - Immunology

JF - Immunology

IS - 4

ER -